Orphan Drug Designation: Tax Credit, Fee Waiver, and Exclusivity

Orphan Drug Designation is an FDA status granted to drugs and biologics intended to treat, diagnose, or prevent rare diseases, and it unlocks a package of financial and regulatory incentives meant to make rare-disease drug development viable. For fiscal year 2026, those incentives include a 25% federal tax credit on qualified clinical testing expenses, a waiver of the New Drug Application user fee worth $4,682,003, and seven years of market exclusivity once the FDA approves the product.¹ Designation is not approval; it’s a status that changes the economics of pursuing approval.

Which Diseases Qualify

A rare disease, under the Orphan Drug Act, is one that affects fewer than 200,000 people in the United States at the time the sponsor submits the designation request.² Prevalence here means people currently diagnosed, not lifetime incidence. For acute diseases lasting less than a year, the FDA looks at annual incidence instead.

A disease that affects more than 200,000 people can still qualify through a second pathway. The sponsor must show there is no reasonable expectation that U.S. sales of the drug will recover the cost of developing and marketing it.³ That argument requires detailed financials: all development costs incurred to date, projected future costs, and projected revenue.

The statutory framework is the Orphan Drug Act of 1983, codified at 21 U.S.C. §§ 360aa–360ee, with implementing regulations at 21 CFR Part 316.⁴

How to Apply

Requests go to the FDA’s Office of Orphan Products Development (OOPD).⁵ A sponsor can file at any point in development, from preclinical work through late-stage trials, as long as the request comes in before the marketing application.

The submission has two required pieces. The first is a scientific rationale showing a medically plausible basis for using the drug against the rare disease, backed by lab data, animal studies, or human experience. The second is documentation that the disease meets the size threshold: prevalence estimates with sources and literature citations for the standard pathway, or a full cost-recovery analysis for the over-200,000 alternative.⁴

Under the Orphan Drug Modernization Plan, the FDA committed to responding to new designation requests within 90 days.⁶ A single drug can hold multiple designations if the sponsor targets different rare diseases with the same product.

What Designation Gets You

25% Tax Credit on Clinical Testing

Sponsors can claim a federal tax credit equal to 25% of qualified clinical testing expenses incurred on the designated drug.⁷ The rate dropped from 50% under the Tax Cuts and Jobs Act, effective for tax years beginning after 2017. Unused credit carries forward, which matters for sponsors operating at a loss during development.

Qualified clinical testing expenses generally track the definition of qualified research expenses under Section 41 of the Internal Revenue Code, substituting “clinical testing” for “qualified research.” That covers wages, supplies, and contract research tied to human trials on the designated indication. Sponsors claim the credit on IRS Form 8820.⁸

Waiver of the PDUFA User Fee

New Drug Applications and Biologics License Applications carry a substantial user fee under the Prescription Drug User Fee Act. For fiscal year 2026, that fee is $4,682,003 for applications requiring clinical data.¹ Orphan-designated products are exempt, but only if the application covers the designated rare disease alone. Adding a non-orphan indication to the same application forfeits the waiver.

Orphan Products Grants

The FDA’s Orphan Products Grants Program funds clinical studies directly, covering drugs, biologics, medical devices, and medical foods. Chronic-disease products need a U.S. prevalence below 200,000; acute diseases use annual incidence against the same threshold.⁹ The grants support clinical work rather than preclinical research, so applicants typically need to be past the earliest stages.

Seven Years of Market Exclusivity

Once the FDA approves an orphan-designated drug for its designated rare disease, the sponsor gets seven years of exclusive marketing rights.¹⁰ During that window, the FDA will not approve another application for the same drug for the same disease. The block covers generics and other brand-name applications for the identical product and indication.

Three exceptions can let a competing application through:

The exclusivity holder cannot produce enough of the drug to meet patient needs.
The exclusivity holder consents to a competing approval.
A subsequent sponsor demonstrates that its version is clinically superior, meaning it offers a significant therapeutic advantage in safety, effectiveness, or a major contribution to patient care.⁵

Pediatric Study Exemption

The Pediatric Research Equity Act lets the FDA require studies of a drug’s safety and effectiveness in children. Orphan-designated drugs are generally exempt, which can remove years of additional study obligations. Certain oncology products are the exception: they still must undergo pediatric evaluation under the Research to Accelerate Cures and Equity (RACE) Act, orphan designation notwithstanding.

What Designation Does Not Do

Designation does not lower the scientific standard for approval. The product still has to clear the FDA’s full safety and efficacy review, the same review any drug faces.⁵ What often changes in practice is the shape of the evidence: because rare diseases make large trial enrollment genuinely difficult, the FDA may accept a single well-controlled study rather than the two typical for common conditions.

Designation is also not, by itself, a faster review track. Many orphan products separately qualify for expedited programs like fast track designation, breakthrough therapy designation, or accelerated approval, and those are what compress the timeline.

When Designation Can Be Revoked

The FDA can revoke an orphan drug designation if the original request contained an untrue statement of material fact, omitted required information, or if the agency later determines the drug was never actually eligible.¹¹

One protection is worth knowing. If a disease’s prevalence grows past 200,000 people after designation is granted, that alone is not grounds for revocation. The threshold is measured at the time of the request, and later population changes do not retroactively disqualify the drug. If the product has already been approved, revoking the designation strips the sponsor’s market exclusivity but does not remove the product from the market. The approval itself stands.

1
Food and Drug Administration. Prescription Drug User Fee Amendments
2
U.S. Food and Drug Administration. Rare Diseases at FDA
3
Food and Drug Administration. Drug Development for Very Rare Diseases
4
eCFR. 21 CFR Part 316 – Orphan Drugs
5
U.S. Food and Drug Administration. Designating an Orphan Product: Drugs and Biological Products
6
U.S. Food and Drug Administration. FDA’s Orphan Drug Modernization Plan
7
Office of the Law Revision Counsel. 26 USC 45C – Clinical Testing Expenses for Certain Drugs for Rare Diseases or Conditions
8
Internal Revenue Service. About Form 8820, Orphan Drug Credit
9
Grants.nih.gov. Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases
10
U.S. Food and Drug Administration. Patents and Exclusivity
11
eCFR. 21 CFR 316.29 – Revocation of Orphan-Drug Designation